CA2263999A1 - Antagonistes de l'integrine - Google Patents
Antagonistes de l'integrine Download PDFInfo
- Publication number
- CA2263999A1 CA2263999A1 CA002263999A CA2263999A CA2263999A1 CA 2263999 A1 CA2263999 A1 CA 2263999A1 CA 002263999 A CA002263999 A CA 002263999A CA 2263999 A CA2263999 A CA 2263999A CA 2263999 A1 CA2263999 A1 CA 2263999A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- aryl
- oxo
- tetrahydro
- naphthyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
L'invention porte sur certains composés nouveaux et leurs dérivés, leur synthèse et leur utilisation en tant qu'antagonistes du récepteur de la vitronectine. Lesdits composés antagonistes du récepteur de la vitronectine sont des antagonistes .alpha.v.beta.3, des antagonistes .alpha.v.beta.5 ou des antagonistes doubles .alpha.v.beta.3/.alpha.v.beta.5, qui servent à inhiber la résorption osseuse, prévenir et traiter l'ostéoporose et inhiber la resténose, la rétinopathie diabétique, la dégénérescence maculaire, l'angiogénèse, l'athérosclérose, l'inflammation et la croissance de tumeurs.
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2512396P | 1996-08-29 | 1996-08-29 | |
US60/025,123 | 1996-08-29 | ||
US3357996P | 1996-12-19 | 1996-12-19 | |
US60/033,579 | 1996-12-19 | ||
GBGB9703015.9A GB9703015D0 (en) | 1997-02-13 | 1997-02-13 | Alpha v B3 antagonists |
GB9703015.9 | 1997-02-13 | ||
US4717797P | 1997-05-20 | 1997-05-20 | |
US60/047,177 | 1997-05-20 | ||
PCT/US1997/014912 WO1998008840A1 (fr) | 1996-08-29 | 1997-08-25 | Antagonistes de l'integrine |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2263999A1 true CA2263999A1 (fr) | 1998-03-05 |
Family
ID=27451604
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002263999A Abandoned CA2263999A1 (fr) | 1996-08-29 | 1997-08-25 | Antagonistes de l'integrine |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0934305A4 (fr) |
JP (1) | JP2002511052A (fr) |
AU (1) | AU724191B2 (fr) |
CA (1) | CA2263999A1 (fr) |
WO (1) | WO1998008840A1 (fr) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6211184B1 (en) | 1996-08-29 | 2001-04-03 | Merck & Co., Inc. | Integrin antagonists |
US6211191B1 (en) | 1997-12-17 | 2001-04-03 | Merck & Co., Inc. | Integrin receptor antagonists |
US6017926A (en) * | 1997-12-17 | 2000-01-25 | Merck & Co., Inc. | Integrin receptor antagonists |
US6066648A (en) | 1997-12-17 | 2000-05-23 | Merck & Co., Inc. | Integrin receptor antagonists |
US6048861A (en) * | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
ATE542797T1 (de) | 1998-04-09 | 2012-02-15 | Meiji Seika Pharma Co Ltd | Aminopiperidinderivate als integrin alpha v beta 3 antagonisten |
EP1070060A1 (fr) * | 1998-04-10 | 2001-01-24 | G.D. Searle & Co. | Derives heterocycliques de glycil beta-alanine agissant comme antagonistes de la vitronectine |
US6689754B1 (en) | 1998-04-10 | 2004-02-10 | G. D. Searle & Co. | Heterocyclic glycyl β-alanine derivatives |
AU3561099A (en) * | 1998-04-14 | 1999-11-01 | American Home Products Corporation | Acylresorcinol derivatives as selective vitronectin receptor inhibitors |
AU3817899A (en) * | 1998-04-15 | 1999-11-01 | Inserm | Therapy of atherosclerosis |
DE69942159D1 (de) * | 1998-06-11 | 2010-04-29 | Ortho Mcneil Pharm Inc | Pyrazine Protease Inhibitore |
CA2338878A1 (fr) * | 1998-08-13 | 2000-02-24 | Merck & Co., Inc. | Antagonistes de recepteurs d'integrine |
PT997474E (pt) | 1998-08-14 | 2004-01-30 | Pfizer | Agentes antitromboticos |
JP2002536411A (ja) | 1999-02-09 | 2002-10-29 | ブリストル−マイヤーズ スクイブ カンパニー | Xa因子のラクタム系阻害剤および方法 |
TR200102944T2 (tr) * | 1999-04-13 | 2002-08-21 | Basf Aktiengesellschaft | İntegrin reseptör ligandları |
RU2255933C9 (ru) * | 1999-05-07 | 2005-11-20 | Тексэс Байотекнолоджи Копэрейшн | ПРОИЗВОДНЫЕ ПРОПИОНОВОЙ КИСЛОТЫ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ СЕЛЕКТИВНОГО ИНГИБИРОВАНИЯ СВЯЗЫВАНИЯ α4β1 ИНТЕГРИНА |
US6867217B1 (en) | 1999-05-19 | 2005-03-15 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade |
US6458952B1 (en) | 1999-05-19 | 2002-10-01 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade |
US6750342B1 (en) | 1999-05-19 | 2004-06-15 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade |
US6653316B1 (en) | 1999-05-19 | 2003-11-25 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade |
US6664255B1 (en) | 1999-05-19 | 2003-12-16 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade |
US7015230B1 (en) | 1999-05-19 | 2006-03-21 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade |
US6716838B1 (en) | 1999-05-19 | 2004-04-06 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents |
PL353364A1 (en) | 1999-06-02 | 2003-11-17 | Merck & Co, Inc. | Alpha v integrin receptor antagonists |
EP1065208A1 (fr) * | 1999-07-02 | 2001-01-03 | Aventis Pharma Deutschland GmbH | Dérivés substitués de la purine inhibiteurs de l'adhésion cellulaire |
EP1065207A1 (fr) * | 1999-07-02 | 2001-01-03 | Aventis Pharma Deutschland GmbH | Dérivées de la naphthyridine, procédés pour leur preparation, leur utilisation, et compositions pharmaceutique les contenant |
ATE344249T1 (de) | 1999-07-19 | 2006-11-15 | Merck Frosst Canada Ltd | Pyrazinone, diese verbindungen enthaltende zusammenstellungen |
WO2001010844A1 (fr) | 1999-08-05 | 2001-02-15 | Meiji Seika Kaisha, Ltd. | DERIVES D'ACIDE φ-AMINO-α-HYDROXYCARBOXYLIQUE POSSEDANT UN ANTAGONISME αvβ3 D'INTEGRINE |
AU7743400A (en) | 1999-10-04 | 2001-05-10 | Merck & Co., Inc. | Integrin receptor antagonists |
DE60037750T2 (de) * | 1999-10-06 | 2009-01-08 | Abbott Gmbh & Co. Kg | Zusammensetzung enthaltend einen tnf-alpha inhibitor und einen integrin alphavbeta3 rezeptorantagonist |
US7182953B2 (en) * | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
CA2397194C (fr) * | 2000-01-20 | 2011-05-17 | Mark E. Duggan | Antagonistes du recepteur de l'integrine alpha v |
US6660885B2 (en) | 2000-03-13 | 2003-12-09 | Pharmacia Corporation | Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade |
EP1268463B1 (fr) | 2000-04-05 | 2005-02-16 | Pharmacia Corporation | 4-pyrones polycycliques a substitution aryle et heteroaryle utiles pour l'inhibition selective de la cascade de coagulation |
JP2004505013A (ja) | 2000-04-05 | 2004-02-19 | ファルマシア・コーポレーション | 凝固カスケードを選択的に阻害するのに有用な多環式アリール及びヘテロアリール置換4−ピリドン類 |
JP2004501077A (ja) | 2000-04-17 | 2004-01-15 | ファルマシア・コーポレーション | 凝固カスケードの選択的阻害に有用な多環式アリールおよびヘテロアリール置換1,4−キノン |
US6511973B2 (en) | 2000-08-02 | 2003-01-28 | Bristol-Myers Squibb Co. | Lactam inhibitors of FXa and method |
US7015223B1 (en) | 2000-11-20 | 2006-03-21 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl 1,2,4-triazinones useful for selective inhibition of the coagulation cascade |
MXPA03004458A (es) | 2000-11-20 | 2005-01-25 | Pharmacia Corp | Arilpiridinas y heteroarilpiridinas sustituidas utiles para inhibicion selectiva de la cascada de coagulacion. |
US7119094B1 (en) | 2000-11-20 | 2006-10-10 | Warner-Lambert Company | Substituted polycyclic aryl and heteroarpyl pyrazinones useful for selective inhibition of the coagulation cascade |
EP1358178A2 (fr) | 2001-01-30 | 2003-11-05 | Bristol-Myers Squibb Company | Lactames sulfonamide inhibiteurs de facteur xa (fxa) et technique |
KR100861466B1 (ko) | 2001-04-24 | 2008-10-02 | 메르크 파텐트 게엠베하 | 항혈관형성제 및 TNFα를 이용한 병용 요법 |
EP1426360A4 (fr) | 2001-09-12 | 2006-04-12 | Kaken Pharma Co Ltd | Derive d'acide 2-phenyle-3-heteroarylpropionique ou son sel et medicaments le contenant |
WO2003029216A1 (fr) | 2001-10-03 | 2003-04-10 | Pharmacia Corporation | Composes heterocycliques a 6 chainons utiles dans l'inhibition selective de la cascade de la coagulation |
WO2003093242A2 (fr) | 2001-10-03 | 2003-11-13 | Pharmacia Corporation | Composes polycycliques a 5 elements substitues pour l'inhibition selective de la cascade de reactions dans la coagulation sanguine |
US20030171368A1 (en) * | 2002-02-06 | 2003-09-11 | Werner Seitz | Pyrimidinonesulfamoylureas` |
CA2610400A1 (fr) * | 2005-06-07 | 2006-12-14 | Pharmacopeia, Inc. | Inhibiteurs d'azinone et de diazinone v3 utilises dans les troubles lies a la depression et au stress |
ES2425396T3 (es) | 2006-01-18 | 2013-10-15 | Merck Patent Gmbh | Terapia específica usando ligandos de integrinas para el tratamiento del cáncer |
WO2008087025A2 (fr) | 2007-01-18 | 2008-07-24 | Merck Patent Gmbh | Thérapie spécifique et médicament utilisant des ligands d'intégrine ou traitant le cancer |
EP2445534A2 (fr) | 2009-05-25 | 2012-05-02 | Merck Patent GmbH | Administration continue du cilengitide dans des traitements du cancer |
HUE057203T2 (hu) | 2013-09-24 | 2022-04-28 | Fujifilm Corp | Új nitrogén-tartalmú vegyület vagy sója, vagy azok fémkomplexe |
RU2016146826A (ru) | 2014-05-30 | 2018-07-04 | Пфайзер Инк. | Производные карбонитрилов как селективные модуляторы андрогенового рецептора |
TW201835078A (zh) | 2017-02-28 | 2018-10-01 | 美商萊築理公司 | αvβ6整合蛋白之抑制劑 |
MA47692A (fr) | 2017-02-28 | 2020-01-08 | Morphic Therapeutic Inc | Inhibiteurs de l'intégrine (alpha-v) (bêta-6) |
EP3617206A1 (fr) | 2018-08-29 | 2020-03-04 | Morphic Therapeutic, Inc. | Inhibiteurs d'intégrine |
WO2023275715A1 (fr) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Métabolites de modulateurs sélectifs du récepteur des androgènes |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5260277A (en) * | 1990-09-10 | 1993-11-09 | Tanabe Seiyaku Co., Ltd. | Guanidinyl and related cell adhesion modulation compounds |
US5416099A (en) * | 1991-10-29 | 1995-05-16 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
AU674553B2 (en) * | 1992-10-14 | 1997-01-02 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
WO1995014683A1 (fr) * | 1993-11-24 | 1995-06-01 | The Du Pont Merck Pharmaceutical Company | Nouveaux antagonistes de recepteur de fibrinogene, a base d'isoxazoline et d'isoxazole |
DE69411584T2 (de) * | 1993-11-24 | 1998-12-17 | Du Pont Merck Pharma | Isoxazoline derivate anwendbar als fibrinogen rezeptor antagonisten |
US5563158A (en) * | 1993-12-28 | 1996-10-08 | The Dupont Merck Pharmaceutical Company | Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists |
US5534524A (en) * | 1994-05-09 | 1996-07-09 | Board Of Regents, The University Of Texas System | Suppression of bone resorption by quinolines |
US5741796A (en) * | 1994-05-27 | 1998-04-21 | Merck & Co., Inc. | Pyridyl and naphthyridyl compounds for inhibiting osteoclast-mediated bone resorption |
US5668159A (en) * | 1996-05-08 | 1997-09-16 | The Dupont Merck Pharmaceutical Company | 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as IIb/IIIa antagonists |
-
1997
- 1997-08-25 AU AU40865/97A patent/AU724191B2/en not_active Ceased
- 1997-08-25 CA CA002263999A patent/CA2263999A1/fr not_active Abandoned
- 1997-08-25 WO PCT/US1997/014912 patent/WO1998008840A1/fr not_active Application Discontinuation
- 1997-08-25 EP EP97938568A patent/EP0934305A4/fr not_active Withdrawn
- 1997-08-25 JP JP51178398A patent/JP2002511052A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP0934305A1 (fr) | 1999-08-11 |
JP2002511052A (ja) | 2002-04-09 |
AU4086597A (en) | 1998-03-19 |
EP0934305A4 (fr) | 2001-04-11 |
AU724191B2 (en) | 2000-09-14 |
WO1998008840A1 (fr) | 1998-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2263999A1 (fr) | Antagonistes de l'integrine | |
US5981546A (en) | Integrin antagonists | |
EP0946165B1 (fr) | Antagonistes de l'integrine | |
US6090944A (en) | Alkanoic acid derivatives as αv integrin receptor antagonists | |
AU717283B2 (en) | Integrin antagonists | |
AU729869B2 (en) | Integrin antagonists | |
US6040311A (en) | Integrin receptor antagonists | |
US6413955B1 (en) | Integrin receptor antagonists | |
US5919792A (en) | Integrin antagonists | |
US6268378B1 (en) | Integrin receptor antagonists | |
US6017925A (en) | Integrin antagonists | |
US6358970B1 (en) | Integrin receptor antagonists | |
AU1914499A (en) | Integrin receptor antagonists | |
US5952341A (en) | Integrin antagonists | |
US6211184B1 (en) | Integrin antagonists | |
US6211191B1 (en) | Integrin receptor antagonists | |
CA2268916A1 (fr) | Antagonistes de l'integrine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |